Work with thought leaders and academic experts in Oncology
Companies can greatly benefit from working with an expert in the field of Oncology. Here are a few reasons why: 1. Cutting-edge Research: Oncology experts stay updated with the latest advancements in cancer research, providing valuable insights and innovative solutions. 2. Clinical Trials: Collaborating with an Oncology researcher allows companies to conduct clinical trials, accelerating the development of new treatments and therapies. 3. Expertise in Precision Medicine: Oncology researchers specialize in personalized medicine, helping companies develop targeted therapies based on individual patient characteristics. 4. Access to Networks: Academic researchers in Oncology have extensive networks within the medical community, providing access to key opinion leaders, clinicians, and other experts. 5. Regulatory Compliance: Oncology experts are well-versed in regulatory requirements, ensuring companies meet all necessary guidelines and standards.
Researchers on NotedSource with backgrounds in Oncology include Ramy Ayoub, Luca Delfinis, Dr. Michael W. Craige, PhD, MBA, Boris Leibovitch, Garrett A. Perchetti, Research Scientist - Virology, Dushani L. Palliyaguru, Ph.D., Burcu Vitrinel, Ph.D., and John M Baust, Ph.D.
Ramy Ayoub
PhD Medical Biophysics
Most Relevant Research Expertise
Other Research Expertise (10)
About
Most Relevant Publications (2+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
Neuro-Oncology / Jun 01, 2022
Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452
See Full Profile
Dr. Michael W. Craige, PhD, MBA
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Most Relevant Research Expertise
Other Research Expertise (5)
About
Most Relevant Publications (1+)
3 total publications
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Frontiers in Oncology / Sep 06, 2023
Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168
See Full Profile
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Expertise
Other Research Expertise (8)
About
Most Relevant Publications (5+)
22 total publications
Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells
Oncotarget / Aug 19, 2016
Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer
Oncotarget / Jun 07, 2016
Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics / Aug 01, 2015
Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t
Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer
Oncotarget / Oct 09, 2015
Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048
Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1
Translational Oncology / Feb 01, 2022
Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320
See Full Profile
Garrett A. Perchetti, Research Scientist - Virology
Research Scientist and MD Candidate in virology with publications on infectious diseases, laboratory medicine, viral genetics, and clinical medicine
Most Relevant Research Expertise
Other Research Expertise (14)
About
Most Relevant Publications (2+)
28 total publications
20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
Open Forum Infectious Diseases / Nov 01, 2021
Zamora, D., Perchetti, G., Biernacki, M., Xie, H., Castor, J. L., Joncas-schronce, L., Blazevic, R., Leisenring, W., Huang, M.-L., Jerome, K., Martin, P. J., Boeckh, M., & Greninger, A. L. (2021). 20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis. Open Forum Infectious Diseases, 8(Supplement_1), S13–S14. https://doi.org/10.1093/ofid/ofab466.020
2626. Rhinovirus in Children Presenting to the Emergency Department: Role of Viral Load in Disease Severity and Co-Infections
Open Forum Infectious Diseases / Oct 01, 2019
Waghmare, A., Strelitz, B., Lacombe, K., Perchetti, G., Nalla, A., Rha, B., Midgley, C., Lively, J. Y., Klein, E. J., Kuypers, J., & Englund, J. A. (2019). 2626. Rhinovirus in Children Presenting to the Emergency Department: Role of Viral Load in Disease Severity and Co-Infections. Open Forum Infectious Diseases, 6(Supplement_2), S915–S916. https://doi.org/10.1093/ofid/ofz360.2304
See Full Profile
Dushani L. Palliyaguru, Ph.D.
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Expertise
Other Research Expertise (16)
About
Most Relevant Publications (1+)
20 total publications
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
Seminars in Oncology / Feb 01, 2016
Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013
See Full Profile
John M Baust, Ph.D
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Expertise
Other Research Expertise (16)
About
Most Relevant Publications (14+)
68 total publications
Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate
Technology in Cancer Research & Treatment / Apr 01, 2007
Baust, J. G., Gage, A. A., Klossner, D., Clarke, D., Miller, R., Cohen, J., Katz, A., Polascik, T., Clarke, H., & Baust, J. M. (2007). Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate. Technology in Cancer Research & Treatment, 6(2), 97–109. https://doi.org/10.1177/153303460700600206
Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death
Technology in Cancer Research & Treatment / Apr 01, 2007
Clarke, D. M., Robilotto, A. T., Rhee, E., VanBuskirk, R. G., Baust, J. G., Gage, A. A., & Baust, J. M. (2007). Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death. Technology in Cancer Research & Treatment, 6(2), 69–79. https://doi.org/10.1177/153303460700600203
Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques
Technology in Cancer Research & Treatment / Apr 01, 2007
Robilotto, A. T., Clarke, D., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2007). Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques. Technology in Cancer Research & Treatment, 6(2), 81–89. https://doi.org/10.1177/153303460700600204
Integrin involvement in freeze resistance of androgen-insensitive prostate cancer
Prostate Cancer and Prostatic Diseases / Jan 12, 2010
Baust, J. G., Klossner, D. P., VanBuskirk, R. G., Gage, A. A., Mouraviev, V., Polascik, T. J., & Baust, J. M. (2010). Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 13(2), 151–161. https://doi.org/10.1038/pcan.2009.59
Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model
Prostate Cancer and Prostatic Diseases / Jan 11, 2011
Santucci, K. L., Snyder, K. K., Baust, J. M., Van Buskirk, R. G., Mouraviev, V., Polascik, T. J., Gage, A. A., & Baust, J. G. (2011). Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer and Prostatic Diseases, 14(2), 97–104. https://doi.org/10.1038/pcan.2010.52
Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model
Prostate Cancer and Prostatic Diseases / Dec 11, 2012
Robilotto, A. T., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2012). Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer and Prostatic Diseases, 16(1), 41–49. https://doi.org/10.1038/pcan.2012.48
Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue
Prostate Cancer and Prostatic Diseases / Jan 27, 2015
Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87–95. https://doi.org/10.1038/pcan.2014.54
Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation
Technology in Cancer Research & Treatment / Jun 23, 2016
Baumann, K. W., Baust, J. M., Snyder, K. K., Baust, J. G., & Van Buskirk, R. G. (2016). Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation. Technology in Cancer Research & Treatment, 16(4), 393–405. https://doi.org/10.1177/1533034616655658
Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer
Technology in Cancer Research & Treatment / Jul 08, 2016
Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2016). Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer. Technology in Cancer Research & Treatment, 15(4), 609–617. https://doi.org/10.1177/1533034616648059
Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model
Technology in Cancer Research & Treatment / May 17, 2017
Baust, J. M., Robilotto, A., Snyder, K. K., Santucci, K., Stewart, J., Van Buskirk, R., & Baust, J. G. (2017). Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model. Technology in Cancer Research & Treatment, 16(6), 900–909. https://doi.org/10.1177/1533034617708960
Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model
Cancer Control / Jan 01, 2018
Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 25(1), 107327481875741. https://doi.org/10.1177/1073274818757418
Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome
Technology in Cancer Research & Treatment / Jan 01, 2018
Baust, J. M., Rabin, Y., Polascik, T. J., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research & Treatment, 17, 153303381876220. https://doi.org/10.1177/1533033818762207
Evaluation of a Novel Cystoscopic Compatible Cryocatheter for the Treatment of Bladder Cancer
Bladder Cancer / Sep 21, 2020
Baust, J. M., Robilotto, A., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., Katz, A., Corcoran, A., & Baust, J. G. (2020). Evaluation of a Novel Cystoscopic Compatible Cryocatheter for the Treatment of Bladder Cancer. Bladder Cancer, 6(3), 303–318. https://doi.org/10.3233/blc-200321
Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model
Breast Cancer: Basic and Clinical Research / Jan 01, 2020
Snyder, K. K., Van Buskirk, R. G., Baust, J. G., & Baust, J. M. (2020). Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model. Breast Cancer: Basic and Clinical Research, 14, 117822342097236. https://doi.org/10.1177/1178223420972363
See Full Profile
Example Oncology projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Oncology?
Development of Targeted Cancer Therapies
An Oncology expert can collaborate with a pharmaceutical company to develop targeted therapies that specifically attack cancer cells, minimizing side effects and improving patient outcomes.
Identification of Biomarkers for Early Cancer Detection
Working with an Oncology researcher, a diagnostic company can identify biomarkers that indicate the presence of cancer at an early stage, enabling early detection and intervention.
Improving Radiation Therapy Techniques
Collaborating with an Oncology expert, a medical device company can enhance radiation therapy techniques, improving precision and minimizing damage to healthy tissues.
Development of Personalized Treatment Plans
An Oncology researcher can assist a healthcare provider in developing personalized treatment plans for cancer patients, considering individual characteristics and genetic profiles.
Exploring Immunotherapy Approaches
Working with an Oncology expert, a biotech company can explore novel immunotherapy approaches for cancer treatment, harnessing the power of the immune system to fight cancer cells.